• News
  • SAN DIEGO
  • BioTech

Orexigen resubmits Contrave to FDA

Orexigen Therapeutics Inc. (Nasdaq: OREX) has resubmitted its Contrave new drug application to the U.S. Food and Drug Administration.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Orexigen Therapeutics Inc.

Company Website

3344 North Torrey Pines Ct. Ste., 200
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
OREX
4.77
  0.01  
+ 0.21%
987,435,000
9.37
3.11

Orexigen Therapeutics Inc. Executive(s):

Michael Narachi

  • Chief Executive Officer, President
Subscribe Today!